Pfizer Inc. (NYSE:PFE) Shares Purchased by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 479,885 shares of the biopharmaceutical company’s stock after buying an additional 26,279 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in Pfizer were worth $13,427,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in Pfizer by 4.9% during the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after purchasing an additional 11,099,024 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer during the 4th quarter worth about $2,129,927,000. Van ECK Associates Corp grew its holdings in shares of Pfizer by 1.8% during the second quarter. Van ECK Associates Corp now owns 16,104,088 shares of the biopharmaceutical company’s stock worth $450,593,000 after buying an additional 290,760 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Pfizer by 3.3% in the second quarter. Federated Hermes Inc. now owns 14,923,545 shares of the biopharmaceutical company’s stock valued at $417,561,000 after buying an additional 470,003 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Pfizer by 2.4% during the second quarter. Envestnet Asset Management Inc. now owns 10,260,067 shares of the biopharmaceutical company’s stock valued at $287,077,000 after buying an additional 238,850 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $29.27 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market cap of $165.86 billion, a PE ratio of -487.75, a P/E/G ratio of 1.04 and a beta of 0.68. The company’s fifty day simple moving average is $29.21 and its 200-day simple moving average is $28.12. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.42.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company posted $0.67 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.74%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, September 9th. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Barclays raised their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group upped their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.